



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q3

2024

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO
ANDREAS LÖSLER, CFO

November 7, 2024

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q3 2024

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS

Further growth in EBITDA also confirmed in Q 3



Group sales above previous year with strong shifts between segments

Strong increase in EBITDA as a result from sales shifts to Specialty Chemicals



Sales outlook 2024 confirmed but is expected in the lower range of the prediction

EBITDA outlook 2024 still valid due to the continued high profitability



Specialty Chemicals and Basics & Intermediates both showed a good EBITDA growth




Alzchem Group AG receives platinum rating for sustainable corporate governance for the first time



Inclusion in the SDAX achieved by the positive and consistent business development




Growth plans in Nitroguanidine business finalized with support from customers and US government



Ongoing strong market situation in niche markets


"VERBUND" SYSTEM – FULLY INTEGRATED BUSINESS MODEL

Ability to adapt production to meet changing end market needs




"VERBUND" SYSTEM – FULLY INTEGRATED BUSINESS MODEL

Step 1 – Capacity increase in Germany



"VERBUND" SYSTEM – FULLY INTEGRATED BUSINESS MODEL

Step 2 – New production plant in USA



LARGEST INVESTMENT IN THE COMPANY'S HISTORY

Alzchem to expand capacities in Germany and starts site selection in US



STEP 1

2024

end of 2026



Major raw material for



Guanidine Nitrate

- Renew and expand the existing facilities
- Double capacity for Guanidine Nitrate

Nitroguanidine (NQ)

- New production plant
- Double capacity for Nitroguanidine

TOTAL INVESTMENT

~ EUR 140 million

FINANCING

Guanidine Nitrate: EUR 34.4 million grant by the EU Commission

Nitroguanidine: Customer framework agreements with non-refundable downpayments

STEP 2

2024

end of 2026

end of 2029



Site search

Construction

Capacity expansion in the US

TOTAL INVESTMENT

~ USD 150 million grant

FINANCING

US Department of Defense

AGENDA – ANALYST PRESENTATION Q3 2024

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)


Challenging market environment with positive EBITDA development




SALES




EBITDA



SALES



EBITDA




SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	- 5.4%	- 5.2%
Price	- 2.2%	- 5.2%
Currency	0.1%	- 0.1%

COMMENTS

- Sales declined as expected in the first nine months of the year driven by
 - Targeted volume effects in low margin businesses
 - Decrease in important raw material prices led to lower sales due to price-adjustment clauses
 - Challenging economic situation in European steel market
- Persistent focus on business with profitable pricing is a key factor for the positive EBITDA development
- Asian competitors still strongly price aggressive in NITRALZ® and Pharma business
- Perlka® business with positive sales development compared to last year



CREAMINO Dormex® Bioselect® **DYHARD®**  **Creapure®**

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)




Ongoing growth trend accompanied by profitability increase


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	+ 11.1%	+ 11.3%
Price	+ 4.7%	+ 2.2%
Currency	- 0.3%	- 0.1%

COMMENTS

- Growth of first half year continued
- Specialty products prove to decouple from the overall chemical industry
- Sales increase driven by almost all products
- Area of contract manufacturing is still linked to the development in European chemical industry and thus behind prior year figures
- Overall, the strong volume growth combined with the positive price development resulted in a significant increase in EBITDA and EBITDA-margin compared to prior year



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)


Segment in line with Outlook




SALES




SALES



EBITDA



EBITDA



COMMENTS

- Sales development in line with pass through of cost increases
- EBITDA influenced by higher grid fees due to past capex projects

FINANCIAL OVERVIEW

Continued growth in all major performance figures



Alzchem Group	Q3 2023	Q3 2024	qoq %	2023 1 - 9	2024 1 - 9	yoy %
SALES (in M€)	120.8	128.9	+6.7%	397.9	415.2	+4.4%
EBITDA (in M€)	19.5	24.9	+27.4%	56.3	76.8	+36.4%
EBITDA margin (in %)	16.2%	19.3%	+3.1 pp	14.2%	18.5%	+4.3 pp
Earnings per Share (in €)	0.85	1.22	+43.7%	2.31	3.83	+65.8%

- Group sales with increase of 4.4% with different development in segments; volume increase over the whole group
- EBITDA strongly impacted by continuous revenue shift to Specialty Chemicals segment, increase by 36.4 % to EUR 76.8 million
- EBITDA-margin increased to 18.5% (previous year: 14.2%) supported by both operating segments
- Stable cost structure and improved financial result led to an increase in EPS of 65.8%


SALES ANALYSIS	DELTA Q3	DELTA 01 - 09
Volume	+4.8%	+5.0%
Price	+2.0%	-0.5%
Currency	-0.1%	-0.1%

BALANCE SHEET (in M€)


Higher investment activity and strong equity ratio of 40%



ASSETS



LIABILITIES




- Balance sheet extension of 55.5 M€ since 2023 driven by strong increase in other current assets and cash amounts
- Higher investment activity results in growing fixed assets
- Inventories and trade receivables on same level as per December 31, 2023
- Strong cash balance of 40.6 M€

- Further growth in equity leads to an equity ratio of 40.1% after 38.5% last period
- Equity positively influenced by good result and increase in interests for pension obligation; oppositely influenced by dividend payment in May
- Increase in interest rates from 3.2% to 3.4% decreased pension provision
- Current liabilities impacted by amounts of EU grants already paid and tax liabilities based on increased tax result
- Repayment of bank liabilities on schedule

CASHFLOW (in M€)

Alzchem has a solid financial basis for upcoming growth investments




- Strong operating cashflow at 75.1 M€ (+30.4 M€ compared to previous year); growth in operating result and strict working capital management are the main drivers for the positive development
- Cashflow from investing activity 12.1 M€ higher than last year
- PV-park completed; creatine expansion on track and first payments for capacity expansion of NQ have already been made
- Free cashflow increased, despite higher capex, to 48.7 M€ compared to 30.5 M€ last year
- Cash flow from financing activity slightly below prior year which was impacted by a refinancing at beginning of 2023
- Factoring and short-term financing lines were not used per September 30th.
- Cash and cash equivalents developed very positively from 11.9 M€ per 31/12/2023 to 40.6 M€ per 30/09/2024;
- Cash surpluses of 12 M€ could be invested on a 3 months fixed interest period and shown in current receivables

OUTLOOK 2024 (in M€)




EBITDA confirmed / sales confirmed but in the lower range of the corridor

SALES



EBITDA



COMMENTS

- Raised EBITDA outlook confirmed
 - EBITDA expected to increase to over 100 M€
 - Most probable expectation is a linear development from half year figures
- Sales outlook for 2024 still valid but will probably end up at the lower end of expectations
- Revenue mix is expected to shift more to Specialty Chemicals
- Main driver of EBITDA development is the continued revenue shift to higher margin specialty products
- EBITDA-margin expected to raise to over 17.5 %
- All other performance measures are confirmed; statements from year end report are still valid

FINANCIAL CALENDAR

Upcoming dates*



NOV 13	2024	Münchner Kapitalmarkt Konferenz
NOV 25-26	2024	Deutsches Eigenkapitalforum
FEB 28	2025	Annual Report 2024
APR 30	2025	Quarterly Statement 1st Quarter 2025
MAY 8	2025	Annual General Meeting 2025
JUL 30	2025	Half-Year Financial Report 2025
OCT 30	2025	Quarterly Statement 3rd Quarter 2025

*subject to change

FEEDBACK

We appreciate your feedback



Were your expectations met?
Are you missing any content?

WE APPRECIATE YOUR FEEDBACK!

[Link](#)

QR-Code



**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q3 2024

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group




ALZCHEM GROUP (IN T€)	31.12.2023	30.09.2024	Deviation	
Intangible assets	3.664	3.592	-71	-1,9%
Tangible assets	177.281	185.482	8.202	4,6%
Investment properties				
Right of use (assets)	4.855	3.978	-877	-18,1%
Investments accounted for using the equity method				
Financials assets	5	5		
Trade receivables				
Other receivables	1.371	1.446	76	5,5%
<i>there of Deferred tax assets for pensions provisions</i>				
Deferred tax assets	20.921	19.447	-1.474	-7,0%
SUM NON-CURRENT ASSETS	208.096	213.951	5.856	2,8%
Inventories	107.479	107.403	-76	-0,1%
Trade receivables	75.212	75.951	739	1,0%
Financial assets	0		0	-100,0%
Other receivables	19.239	41.867	22.628	117,6%
Income tax receivables	2.769	397	-2.372	-85,7%
Cash and cash equivalents	11.883	40.615	28.732	241,8%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	216.581	266.233	49.651	22,9%
SUM ASSETS	424.677	480.184	55.507	13,1%

ALZCHEM GROUP (IN T€)	31.12.2023	30.09.2024	Deviation	
Share capital	101.763	101.763		
RETAINED EARNINGS (+) / LOSS (-)	144.979	171.723	26.743	18,4%
Other comprehensive income	-21.639	-19.581	2.058	-9,5%
Own shares				
SHARE TO THE SHAREHOLDERS	161.625	190.427	28.802	17,8%
Non-controlling interests	1.934	2.063	128	6,6%
SUM EQUITY	163.559	192.489	28.930	17,7%
Provisions for pensions	100.294	98.122	-2.171	-2,2%
Other provisions	19.691	22.732	3.040	15,4%
Loans	48.665	42.665	-6.000	-12,3%
Finance lease liabilities	3.377	2.464	-912	-27,0%
Trade liabilities				
Other liabilities	171		-171	-100,0%
Deferred tax liabilities	6.289	7.159	870	13,8%
SUM NON-CURRENT LIABILITIES	178.487	173.144	-5.343	-3,0%
Other provisions	3.537	2.369	-1.168	-33,0%
Loans	8.833	8.660	-173	-2,0%
Finance lease liabilities	1.613	1.640	27	1,7%
Finance liabilities				
Trade liabilities	31.554	43.082	11.529	36,5%
Other liabilities	28.930	47.120	18.189	62,9%
Income tax liabilities	8.164	11.680	3.516	43,1%
SUM CURRENT LIABILITIES	82.631	114.551	31.920	38,6%
Sum EQUITY AND LIABILITIES	424.677	480.184	55.507	13,1%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Interest rates increased from 3.2% to 3.4% and led to a net pension decrease of 2.2 M€
- Pension trend (2.25%) and salary trend (3.00%) remain unchanged compared to December 31st, 2023
- Pension payments develop as expected with 1.7 M€ - pension obligation has a long maturity with approx. 30 years payout period

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Deviation (Q3)	
Revenue	150.432	126.599	120.824	142.794	150.064	136.191	128.937		8.113	7%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	916	9.105	147	-13.972	-6.521	12.682	-4.310		-4.457	<-1.000
Other income	5.574	1.906	3.104	3.274	3.558	3.731	3.716		613	20%
Raw materials and consumables used	-76.159	-62.374	-48.544	-38.067	-53.237	-57.999	-40.548		7.997	-16%
Employee benefits expense	-35.262	-36.012	-34.678	-39.684	-40.589	-42.468	-38.100		-3.421	10%
Other expense	-26.583	-21.352	-21.317	-29.295	-28.367	-25.118	-24.813		-3.496	16%
EBITDA	18.917	17.872	19.534	25.049	24.910	27.021	24.883		5.348	27%
Depreciation expense	-6.320	-6.335	-6.574	-6.670	-6.534	-6.453	-6.402		172	-3%
Impairment										
EBIT	12.598	11.537	12.960	18.379	18.375	20.567	18.480		5.520	43%
Investment income										
Other interest and similar income	49	106	661	-434	292	687	450		-211	-32%
Other interest and similar expense	-1.882	-1.661	-1.586	-2.537	-1.454	-1.366	-1.537		49	-3%
Financial result	-1.832	-1.555	-925	-2.971	-1.162	-679	-1.087		-162	18%
Result from associates										
Result from ordinary business	10.765	9.982	12.035	15.408	17.213	19.888	17.393		5.358	45%
Taxes on income and profit	-3.055	-2.742	-3.379	-4.222	-4.977	-5.460	-4.974		-1.595	47%
<i>thereof income tax</i>	-2.946	-2.716	-3.015	-6.431	-4.463	-5.036	-4.473		-1.458	48%
<i>thereof change from deferred taxes</i>	-109	-26	-364	2.209	-514	-424	-501		-137	38%
Annual result	7.710	7.240	8.656	11.185	12.237	14.428	12.419		3.763	43%
<i>thereof minority interests</i>	43	43	43	43	43	43	43			
<i>thereof shares held by shareholders</i>	7.667	7.197	8.613	11.143	12.194	14.385	12.376		3.763	44%
Result per share in EUR	0,76 €	0,71 €	0,85 €	1,09 €	1,20 €	1,41 €	1,22 €			

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

	Q3 2023	Q3 2024	Deviation (QoQ)		YTD Sep.2023	YTD Sep.2024	Deviation (YoY)	
Revenue	120.824	128.937	8.113	6,7%	397.854	415.192	17.337	4,4%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	147	-4.310	-4.457	<-1.000%	10.168	1.852	-8.317	-81,8%
Other income	3.104	3.716	613	19,7%	10.583	11.006	423	4,0%
Raw materials and consumables used	-48.544	-40.548	7.997	-16,5%	-187.077	-151.783	35.294	-18,9%
Employee benefits expense	-34.678	-38.100	-3.421	9,9%	-105.953	-121.156	-15.203	14,3%
Other expense	-21.317	-24.813	-3.496	16,4%	-69.252	-78.297	-9.045	13,1%
EBITDA	19.534	24.883	5.348	27,4%	56.324	76.813	20.489	36,4%
Depreciation expense	-6.574	-6.402	172	-2,6%	-19.229	-19.390	-161	0,8%
Impairment	0	0	0		0	0	0	
EBIT	12.960	18.480	5.520	42,6%	37.095	57.423	20.328	54,8%
Investment income	0	0	0		0	0	0	
Other interest and similar income	661	450	-211	-31,9%	816	1.429	613	75,2%
Other interest and similar expense	-1.586	-1.537	49	-3,1%	-5.129	-4.358	771	-15,0%
Financial result	-925	-1.087	-162	17,5%	-4.312	-2.928	1.384	-32,1%
Result from associates	0	0	0		0	0	0	
Result from ordinary business	12.035	17.393	5.358	44,5%	32.782	54.495	21.713	66,2%
Taxes on income and profit	-3.379	-4.974	-1.595	47,2%	-9.176	-15.411	-6.236	68,0%
<i>thereof income tax</i>	-3.015	-4.473	-1.458	48,3%	-8.677	-13.972	-5.295	61,0%
<i>thereof change from deferred taxes</i>	-364	-501	-137	37,8%	-499	-1.439	-941	188,6%
Annual result	8.656	12.419	3.763	43,5%	23.606	39.083	15.477	65,6%
<i>thereof minority interests</i>	43	43	0	0,0%	128	128	0	0,0%
<i>thereof shares held by shareholders</i>	8.613	12.376	3.763	43,7%	23.478	38.955	15.477	65,9%
Result per share in EUR	0,85 €	1,22 €	0	43,7%	2,31 €	3,83 €	2	65,8%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

Consolidated earnings before taxes

Depreciation on fixed and intangible assets

Decrease in pension provisions

Loss (+) / Profit (-) from the sale of non-current assets

Other non-cash income (-) and expenses (+)

Financial result

Interests & Taxes

Increase (+) / Decrease (-) Net Working Capital

Cashflow from ongoing operations (Net cash flow)

Cash outflows for investments in fixed assets

Cash inflows from the sale of fixed assets

Cash inflows from the disposal of investments

Cashflow from investing activity

Free cashflow

Deposits (+) / Repayment (-) bank loans long-term

Repayment of bank loans long-term

Deposits (+) / Repayment (-) from short-term financing lines

Dividend payments

Payment of reduction in leasing liabilities

Payments for the acquisition of own shares (incl. transaction costs)

Payments to non-controlling interests

Cashflow from financing activity

Net increase / decrease in cash and cash equivalents

	Q3 2023	Q3 2024	1 - 9 2023	1 - 9 2024
Consolidated earnings before taxes	12.035	17.393	32.782	54.495
Depreciation on fixed and intangible assets	6.574	6.402	19.229	19.390
Decrease in pension provisions	-441	-547	-1.408	-1.651
Loss (+) / Profit (-) from the sale of non-current assets	-8	36	-9	33
Other non-cash income (-) and expenses (+)	837	1.420	3.751	9.306
Financial result	925	1.087	4.312	2.928
Interests & Taxes	-4.068	-4.788	-9.513	-8.651
Increase (+) / Decrease (-) Net Working Capital	-10.964	-9.748	-4.440	-766
Cashflow from ongoing operations (Net cash flow)	4.890	11.255	44.705	75.084
Cash outflows for investments in fixed assets	-5.653	-13.892	-14.230	-26.331
Cash inflows from the sale of fixed assets	8	-36	9	-33
Cash inflows from the disposal of investments				
Cashflow from investing activity	-5.645	-13.928	-14.222	-26.364
Free cashflow	-755	-2.673	30.483	48.720
Deposits (+) / Repayment (-) bank loans long-term			30.000	
Repayment of bank loans long-term	-1.735	-2.208	-6.762	-6.187
Deposits (+) / Repayment (-) from short-term financing lines	10.170		-33.863	
Dividend payments			-10.685	-12.212
Payment of reduction in leasing liabilities	-435	-434	-1.331	-1.332
Payments for the acquisition of own shares (incl. transaction costs)				
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	8.000	-2.642	-22.813	-19.902
Net increase / decrease in cash and cash equivalents	7.245	-5.315	7.670	28.819

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES


SALES	2022				2023				2024				Deviation PY (Q3)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%
Basics & Intermediates	57.441	57.927	59.557	52.614	57.337	46.038	44.271	44.538	49.299	41.848	40.927		-3.344	-8%
Specialty Chemicals	65.279	76.214	72.967	73.902	85.783	73.172	69.545	91.302	92.961	85.805	80.354		10.808	16%
Other and Holding	6.675	6.294	6.670	6.684	7.312	7.389	7.007	6.955	7.804	8.538	7.656		649	9%
<i>Group Consolidation</i>														
Alzchem Group	129.395	140.435	139.193	133.200	150.432	126.599	120.824	142.794	150.064	136.191	128.937		8.113	7%

EBITDA

EBITDA	2022				2023				2024				Deviation PY (Q3)	
	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	T€	%
Basics & Intermediates	2.841	853	-2.621	3.910	2.780	2.410	1.065	3.275	1.802	3.055	1.827		761	71%
Specialty Chemicals	14.267	16.322	14.637	7.789	16.019	14.936	18.541	23.747	22.684	22.843	21.749		3.208	17%
Other and Holding	-139	830	1.038	230	475	438	721	-1.171	537	849	1.114		393	54%
<i>Group Consolidation</i>	103	-200	-905	2.487	-357	88	-793	-802	-113	274	194		986	124%
Alzchem Group	17.072	17.805	12.149	14.416	18.917	17.872	19.534	25.049	24.910	27.021	24.883		5.348	27%

ALZCHEM GROUP LOCATIONS

Production sites and sales companies



IMPLEMENTING OPERATING TARGETS 2024

Focus on the key growth drivers and sustainability



IMPROVEMENT

- Pass on raw material price increases to the market
- Flexibilization of production and processes
- Volume growth & full capacity utilization




GROWTH

- Increase the availability of Creamino® worldwide
- Examine growth opportunities in USA
- Accompany market growth of Creapure® through additional CAPEX
- Embed Eminex® on the certificate market



SUSTAINABILITY

- Vision 0 accidents and 0 waste
- Realization of climate roadmap
- Implement EU Taxonomy Regulation and CSRD in an audit-ready manner
- Enjoyment of work – realization of the feedback from the employee survey




"VERBUND" – FULLY INTEGRATED BUSINESS MODEL

Vertically integrated production of chemical products based on the NCN chain



- Segment Specialty Chemicals
- Segment Basics & Intermediates



BENEFITS OF "VERBUND"

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

GLOBAL DEVELOPMENTS AS GROWTH DRIVERS



POPULATION GROWTH



LONGER LIFE EXPECTANCY



CLIMATE CHANGE



SUSTAINABILITY



SAFETY & DEFENCE

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries






	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO [®]	A nutritional additive for poultry and pigs	Feed additive
	Creapure [®]	Creapure [®] , premium brand for creatine monohydrate as ingredient in sports & health nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Creavitalis [®]	Creatine for health and food applications	Food supplements
	Dormex [®]	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex [®]	Plant growth regulator used in fruit production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect [®]	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD [®]	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
Nitroguanidine	Intermediates for explosives and agrochemical products	Agriculture, Automotive, Defense	

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	NITRALZ[®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Eminex [®]	Reduction of methane emissions during storage of manure	Agriculture
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	<p>Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, Master Builders Solution, Sika, Firmenich, Klüh Catering, VIACTIV)</p> <p>Site services</p> <p>Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments</p>		

KEY SHARE DATA

Share details as of November 5, 2024



SHARES OUTSTANDING 10,176,335

LAST CLOSING PRICE EUR 54.60

MARKET CAPITALIZATION EUR 555.6 m

TICKER ACT


WKN A2YNT3

ISIN DE000A2YNT30

LISTING Frankfurt Stock Exchange – Prime Standard

DESIGNATED SPONSOR Baader Bank AG
ODDO BHF SE

SHAREHOLDER STRUCTURE



As of August 2024. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the "Guide to the DAX Equity Indices."